Page 1621 - Saunders Comprehensive Review For NCLEX-RN

function.
B. Side and adverse effects

1. Cough, sneezing, nasal sting, or bronchospasm

following inhalation
2. Unpleasant taste in the mouth
C. Interventions: Monitor respirations and assess lung sounds for
rhonchi or wheezing.

D. Client education

1. To administer oral capsules at least 30 minutes before
meals
2. Not to discontinue the medication abruptly, because a
rebound asthmatic attack can occur

Instruct the client taking inhaled medications to drink a few sips

of water before and after inhalation to prevent a cough and an
unpleasant taste in the mouth.
VII. Monoclonal Antibody (see Box 51-1)
A. Description
1. Omalizumab is a recombinant DNA-derived
humanized immunoglobulin G (IgG) murine
monoclonal antibody that selectively binds to
immunoglobulin E (IgE) to limit the release of
mediators in the allergic response.
2. Used to treat allergy-related asthma; administered
subcutaneously every 2 to 4 weeks
3. Dose is titrated on the basis of the serum IgE level and
body weight.
4. Contraindicated in those with hypersensitivity to the
medication

B. Side and adverse effects

1. Injection site reactions
2. Viral infections
3. Upper respiratory infections
4. Sinusitis
5. Headache
6. Pharyngitis
7. Anaphylaxis
8. Malignancies
C. Interventions
1. Assess respiratory rate, rhythm, and depth, and
auscultate lung sounds.
2. Assess for allergies and/or allergic reaction symptoms
such as rash or urticaria.

1621